A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL

NCT02323230 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped new study

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL: DPX-Survivac
DRUG: Cyclophosphamide

Sponsor

ImmunoVaccine Technologies, Inc. (IMV Inc.)